Publicado en el European Heart Journal – Cardiovascular Pharmacotherapy el estudio, Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT), donde participa el Dr. Gonzalo Pizarro, Jefe de Servicio de Cardiología del Hospital Ruber Juan Bravo.
Xavier Rossello, Sergio Raposeiras-Roubin, Roberto Latini, Alberto Dominguez-Rodriguez, José A Barrabés, Pedro L Sánchez, Manuel Anguita, Felipe Fernández-Vázquez, Domingo Pascual-Figal, José M De la Torre Hernandez, Stefano Ferraro, Alfredo Vetrano, José A Pérez-Rivera, Oscar Prada-Delgado, Noemí Escalera, Lidia Staszewsky, Gonzalo Pizarro, Jaume Agüero, Stuart Pocock, Filippo Ottani, Valentín Fuster, Borja Ibáñez, REBOOT-CNIC investigators
Background
There is a lack of evidence regarding the benefits of β-blocker treatment after invasively managed acute myocardial infarction (MI) without reduced left ventricular ejection fraction (LVEF).